Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia
Yok‐Ai Que(University Hospital of Lausanne), Philippe Eggimann(University Hospital of Lausanne), Jean‐Jacques Rouby(Sorbonne Université), Jean‐Luc Pagani(University of Lausanne), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Anna Rey-Perez(Biognosys (Switzerland)), Qin Lü(Shanghai Jiao Tong University), Bruno François(Inserm), M. Tamm(Tallinn University), Jorge Garbino(University Hospital of Geneva), Erkan Mus(Biognosys (Switzerland)), E. Mercier(Centre Hospitalier Universitaire de Tours), Michel Wolff(Université Paris Cité), Jean‐Pierre Revelly(University Hospital of Lausanne), Jean Chastre(Sorbonne Université), Hedvika Lazar(Biognosys (Switzerland))
European Journal of Clinical Microbiology & Infectious Diseases
May 24, 2014
Cited by 78
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
International evidence-based recommendations for point-of-care lung ultrasound
|Intensive Care Medicine|2012|2.9k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
|New England Journal of Medicine|2018|894